Clinical trials: Demyelinating Disease
Multiple Sclerosis, Autoimmune
Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions
Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via intravascular system of quality of life and…
- Trial name
- cSVF (NCT02939859)
- Testing
- Microcannula Harvest Adipose, Centricyte 1000, Sterile Normal Saline IV deployment AD-cSVF
- Where
- 2 sites in United States, Honduras
- Sponsor
- Healeon Medical Inc
Multiple Sclerosis
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
The primary objective is to assess the quality of life of intramuscular (IM) Interferon Beta-1a in participants with relapsing remitting multiple sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) in a clinical practice…
- Trial name
- AVAIL (NCT01272128)
- Testing
- Interferon beta-1a
- Where
- 17 sites in Belgium
- Volunteers
- 100 people
- Sponsor
- Biogen
Multiple Sclerosis
Tecfidera Slow-Titration Study
The primary objective of the study is to assess whether a 6-week titration (compared with a 1-week titration) is effective in reducing the incidence of dimethyl fumarate (DMF [Tecfidera])-related gastrointestinal (GI) adverse…
- Trial name
- TITRATION (NCT02428231)
- Testing
- dimethyl fumarate
- Where
- 20 sites in United States, Belgium and 2 more
- Volunteers
- 62 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy
The primary objective of the study is to investigate whether topical Vitamin K application reduces the grade of erythema in comparison with a vehicle cream (placebo) through physicians' assessment and participant self-assessment.
- Trial name
- VITALITY (NCT03091569)
- Testing
- Vitamin K Cream
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Biogen
Progressive Multifocal Leukoencephalopathy
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including…
- Trial name
- NCT03399981
- Testing
- Tysabri
- Where
- United States
- Volunteers
- 80,327 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)
This is an open-label, randomized, multicenter, comparative, and parallel-group study comparing the therapeutic effects of two interferon-beta-1a regimens in relapsing-remitting multiple sclerosis (MS).
- Trial name
- NCT00292266
- Testing
- Rebif®, Avonex®
- Volunteers
- 677 people
- Sponsor
- EMD Serono
Relapsing Multiple Sclerosis
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
Open-label, long-term extension study available to participants who have completed CNMAu8.201.
- Trial name
- VISIONMS-LTE (NCT04626921)
- Testing
- CNM-Au8
- Where
- 5 sites in Australia
- Volunteers
- 55 people
- Sponsor
- Clene Nanomedicine
Metachromatic Leukodystrophy (MLD)
Multicenter Study of HGT-1110 Administered Intrathecally in Children With Metachromatic Leukodystrophy (MLD)
The purpose of this study is to determine the safety of ascending doses of HGT-1110 administered by intrathecal (IT) injection for 38 weeks (20 injections) in children with metachromatic leukodystrophy (MLD).
- Trial name
- IDEAMLD (NCT01510028)
- Testing
- Recombinant human arylsulfatase A
- Where
- 5 sites in Australia, Denmark and 3 more
- Volunteers
- 24 people
- Sponsor
- Shire
Multiple Sclerosis
MS-Related Disability Worsening and Thalamic Volume Loss
PENTAGON is an observational, non-interventional, multicenter, prospective cohort study conducted at approximately 20 neurology centers and affiliated radiology centers across Germany.
- Trial name
- PENTAGON (NCT07753928)
- Testing
- Disease-Modifying Therapies (DMTs)
- Where
- 2 sites in Germany
- Volunteers
- 2,400 people
- Sponsor
- Jung Diagnostics GmbH
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study designed to evaluate the safety, tolerability and activity of ibudilast administered twice daily over a 96 week period in subjects with…
- Trial name
- NCT01982942
- Testing
- ibudilast
- Where
- 28 sites in United States
- Volunteers
- 255 people
- Sponsor
- MediciNova
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Multiple Sclerosis
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
The purpose of this study is to evaluate the toxicity and the effectiveness of high dose chemotherapy with HPC transplant Multiple Sclerosis that has failed at least two lines of therapy
- Trial name
- NCT01679041
- Testing
- Alemtuzumab, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Seah Lim M.D.
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT.
- Trial name
- NCT02637856
- Testing
- Ocrelizumab
- Where
- 82 sites in United States, Canada
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
X-linked Adrenoleukodystrophy
Disease Progression in Women With X-linked Adrenoleukodystrophy
Observational, single-site prospective and minimally interventional study in women with X-linked adrenoleukodystrophy (ALD), conducted in France.
- Trial name
- NCT06178120
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Minoryx Therapeutics, S.L.
Multiple Sclerosis, Relapsing-Remitting
A Canadian Study Assessing the Utility of the Treatment Optimization Recommendations in Multiple Sclerosis
The Canadian Multiple Sclerosis Working Group (CMSWG) has developed practical recommendations on how neurologists can assess the status of subjects on disease modifying drugs (DMDs) and decide when it may be necessary to modify…
- Trial name
- CanTOR (NCT01142583)
- Volunteers
- 192 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include: 1.
- Trial name
- NCT01031459
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046)
- Where
- 10 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Bayer
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of…
- Trial name
- Ocarina II (NCT05232825)
- Testing
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV
- Where
- 37 sites in United States, Brazil and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with…
- Trial name
- NCT07483450
- Testing
- Ocrelizumab
- Where
- 17 sites in China
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Evaluate the Safe and Effective Use of the Avonex® Single-Use Autoinjector in Multiple Sclerosis Subjects
The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).
- Trial name
- NCT00828204
- Testing
- single-use autoinjector with a prefilled liquid Avonex syringe, Avonex prefilled syringe via manual IM injection, BG9418 (interferon beta-1a)
- Where
- 16 sites in United States
- Volunteers
- 95 people
- Sponsor
- Biogen
Multiple Sclerosis
Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323
The objective of the study is to evaluate the effect, safety and tolerability of CDP323 in patients with relapsing forms of multiple sclerosis
- Trial name
- NCT00484536
- Testing
- CDP323
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 232 people
- Sponsor
- UCB Pharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.